What's new

Human medicines European public assessment report (EPAR): Nuvaxovid, COVID-19 Vaccine (recombinant, adjuvanted), Date of authorisation: 20/12/2021, Revision: 17, Status: Authorised

Human medicines European public assessment report (EPAR): Nuvaxovid, COVID-19 Vaccine (recombinant, adjuvanted), Date of authorisation: 20/12/2021, Revision: 17, Status: Authorised

Feb 27, 2025 - 16:53
 0
Human medicines European public assessment report (EPAR): Nuvaxovid, COVID-19 Vaccine (recombinant, adjuvanted), Date of authorisation: 20/12/2021, Revision: 17, Status: Authorised
Human medicines European public assessment report (EPAR): Nuvaxovid, COVID-19 Vaccine (recombinant, adjuvanted), Date of authorisation: 20/12/2021, Revision: 17, Status: Authorised
Read More

Tags:

Previous Article

Peru leads the way in embracing STAR to make tourism a pillar of rural development

Next Article

New generation is a ‘better approach’ to energy security than transmission: ERCOT

Related Posts

PSUSA/00003148/202405

PSUSA/00003148/202405

Feb 9, 2025  0

Human medicines European public assessment report (EPAR): Gencebok, caffeine citrate, Date of authorisation: 19/08/2020, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 12, 2025  0

Herbal medicinal product: Salicis cortex, Salix [various species including S. purpurea L.; S. daphnoides Vill.; S. fragilis L.], F: Assessment finalised

Herbal medicinal product: Salicis cortex, Salix [variou...

Apr 1, 2025  0